# SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

> **NCT00006247** · PHASE1 · TERMINATED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 33 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** semaxanib

## Key facts

- **NCT ID:** NCT00006247
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** 2003-07
- **Final completion:** 2006-03
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** The pharmaceutical company discontinued further development of SU5416.
- **Last updated:** 2009-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006247, "SU5416 in Treating Children With Recurrent or Progressive Brain Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00006247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*